Core Laboratories Sees Q1 Adj EPS $0.05-$0.07 vs $0.14 Est; Lowers Q1 Sales Guidance from $124.000M-$130.000M to $119.000M-$123.000M vs $128.290M Est

Benzinga Newsdesk www.benzinga.com Negative 58.4%

Neg 58.4% Neu 0% Pos 0%

Core Laboratories (NYSE:CLB) is looking for Q1 Adj EPS of $0.05-$0.07 vs $0.14 analyst estimate. Lowers Q1 sales outlook from $124.000 million-$130.000 million to $119.000 million-$123.000 million vs $128.290 million estimate.